{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:15:23Z","timestamp":1795011323766,"version":"4.9.1"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe current data of topical calcineurin inhibitors (CIs) during fungal keratitis in combination with antifungal agents and after therapeutic penetrating keratoplasty (TPKP) for fungal keratitis as steroid-sparing anti-inflammatory medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This narrative review was performed with a literature search conducted in PubMed. Full-text articles available in English with no date restrictions were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>CIs attenuate T-lymphocyte activation, which is an important mechanism underlying host immune responses in fungal keratitis. Topical CIs are used off-label in a variety of ocular conditions, including in high-risk PKP to decrease risk of corneal graft rejection. In fungal keratitis, in vitro and experimental animal studies have demonstrated both additive and synergistic effects with cyclosporine A and tacrolimus in combination with antifungals. Retrospective data and community consensus further support the perceived clinical benefit of CIs during active fungal keratitis. Topical cyclosporine use in patients who undergo TPKP for fungal keratitis has demonstrated clinical efficacy as a steroid-sparing agent in both minimizing fungal recurrences while optimizing graft clarity rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although not yet widely adopted in clinical practice, topical CIs represent a promising potential solution to the clinical dilemma of balancing inflammation control while avoiding steroids in fungal keratitis. Based on data from both during fungal keratitis and after TPKP for fungal keratitis, there may be a role in early initiation of CIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ico.0000000000004166","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:00:59Z","timestamp":1778781659000},"page":"1332-1338","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Role of Topical Calcineurin Inhibitors During and After Fungal Keratitis: A Narrative Review"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-7214","authenticated-orcid":false,"given":"Jerry","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ajo.2024.04.009","article-title":"Trends and clinical outcomes of fungal keratitis in Canada: a 20-year retrospective Multicentre Study","volume":"265","author":"Ling","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jamaophthalmol.2013.1612","article-title":"Differences in clinical outcomes in keratitis due to fungus and bacteria","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jtos.2021.12.001","article-title":"Fungal keratitis: a review of clinical presentations, treatment strategies and outcomes","volume":"24","author":"Sharma","year":"2022","journal-title":"Ocul Surf"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/ICO.0000000000003174","article-title":"2023 survey of keratoplasty postoperative steroid management","volume":"42","author":"Boychev","year":"2023","journal-title":"Cornea"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/ICO.0000000000003340","article-title":"Steroids in the management of infectious keratitis","volume":"42","author":"Keenan","year":"2023","journal-title":"Cornea"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12886-019-1212-0","article-title":"Clinical analysis of microbiologically proven fungal keratitis according to prior topical steroid use: a retrospective study in South Korea","volume":"19","author":"Cho","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.4103\/ijo.IJO_1952_18","article-title":"Outcomes of therapeutic penetrating keratoplasty in 198 eyes with fungal keratitis","volume":"67","author":"Mundra","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/ICO.0000000000002044","article-title":"Recurrence of infection in corneal grafts after therapeutic penetrating keratoplasty for microbial keratitis","volume":"39","author":"Chatterjee","year":"2020","journal-title":"Cornea"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"e00247","DOI":"10.1002\/adtp.202500247","article-title":"Fungal keratitis: clinical presentations, mechanism and management strategies","volume":"8","author":"Wang","year":"2025","journal-title":"Adv Ther"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s10439-006-9179-4","article-title":"NFAT and NF\u03baB activation in T lymphocytes: a model of differential activation of gene expression","volume":"34","author":"Fisher","year":"2006","journal-title":"Ann Biomed Eng"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12035-025-05549-2","article-title":"Calcineurin inhibitors: current role, toxicity management, and future frontiers in immunosuppression","volume":"63","author":"Mistry","year":"2025","journal-title":"Mol Neurobiol"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10792-025-03844-4","article-title":"Clinical applications of tacrolimus in the treatment of ocular diseases: a narrative literature review","volume":"46","author":"Alghamdi","year":"2025","journal-title":"Int Ophthalmol"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.3390\/jcm14155347","article-title":"Topical use of tacrolimus in corneal and ocular surface pathologies: a systematic review","volume":"14","author":"Katonis","year":"2025","journal-title":"J Clin Med"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14744\/bej.2024.54765","article-title":"Efficacy and safety of topical tacrolimus for vernal keratoconjunctivitis: a systematic review","volume":"9","author":"Sarsono","year":"2024","journal-title":"Beyoglu Eye J"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/15569527.2025.2485139","article-title":"Adverse effects of topical tacrolimus compounded ophthalmic preparations","volume":"44","author":"Bakather","year":"2025","journal-title":"Cutan Ocul Toxicol"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/OPTH.S115098","article-title":"Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye","volume":"12","author":"Deveney","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jfo.2016.12.004","article-title":"Pan-European survey of the topical ocular use of cyclosporine A","volume":"40","author":"Labb\u00e9","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"R21-20260902","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s40135-017-0119-2","article-title":"Update on the management of high-risk penetrating keratoplasty","volume":"5","author":"Jabbehdari","year":"2017","journal-title":"Curr Ophthalmol Rep"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12886-024-03506-6","article-title":"Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial","volume":"24","author":"Shimazaki","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/bjophthalmol-2013-303639","article-title":"Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study","volume":"97","author":"Magalhaes","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/ICO.0000000000002709","article-title":"Efficacy of immunosuppressants in high rejection risk keratoplasty: a meta-analysis of comparative studies","volume":"40","author":"Yu","year":"2021","journal-title":"Cornea"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1038\/s41433-025-04002-x","article-title":"Efficacy of topical tacrolimus (FK506) in high-risk penetrating keratoplasty: a systematic review and meta-analysis of comparative studies","volume":"39","author":"Qedair","year":"2025","journal-title":"Eye (London, England)"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1038\/s41433-020-01375-z","article-title":"Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: 1-year results of a randomized clinical trial","volume":"35","author":"Faramarzi","year":"2021","journal-title":"Eye"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0021-5155(99)00223-3","article-title":"Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty","volume":"44","author":"Inoue","year":"2000","journal-title":"Jpn J Ophthalmol"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/11206721211023320","article-title":"Topical corticosteroids with topical cyclosporine A versus topical corticosteroids alone for immunological corneal graft rejection","volume":"32","author":"Marques","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00003226-199905000-00012","article-title":"Effects of methylprednisolone and cyclosporine A on fungal growth in vitro","volume":"18","author":"Bell","year":"1999","journal-title":"Cornea"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.44.9.2373-2381.2000","article-title":"Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans","volume":"44","author":"Marchetti","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/jof6030103","article-title":"In vitro interaction between isavuconazole and tacrolimus, cyclosporin A, or sirolimus against aspergillus species","volume":"6","author":"Schwarz","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkz102","article-title":"In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales","volume":"74","author":"Schwarz","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1128\/AAC.00393-06","article-title":"Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy","volume":"50","author":"Onyewu","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"e44192","DOI":"10.1371\/journal.pone.0044192","article-title":"Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"7309","DOI":"10.1167\/iovs.11-7739","article-title":"Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for aspergillus keratitis","volume":"52","author":"Rebong","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"e114386","DOI":"10.1371\/journal.pone.0114386","article-title":"Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"R37-20260902","first-page":"187","article-title":"Tacrolimus interacts with voriconazole to reduce the severity of fungal keratitis by suppressing IFN-related inflammatory responses and concomitant FK506 and voriconazole treatment suppresses fungal keratitis","volume":"24","author":"Zhong","year":"2018","journal-title":"Mol Vis"},{"key":"R38-20260902","first-page":"536","article-title":"Rapamycin liposome gutta inhibiting fungal keratitis of rats","volume":"12","author":"Zhang","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"974","DOI":"10.12669\/pjms.40.5.7777","article-title":"Clinical efficacy of cyclosporin and natamycin for fungal keratitis","volume":"40","author":"Yang","year":"2024","journal-title":"Pak J Med Sci"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/ICO.0000000000003934","article-title":"Adjunctive topical calcineurin inhibitors during the treatment of fungal keratitis: practice patterns and opinions","volume":"44","author":"Christy","year":"2025","journal-title":"Cornea"},{"key":"R41-20260902","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10792-007-9180-4","article-title":"Regression of severe corneal stromal neovascularization with topical cyclosporine 0.05% after penetrating keratoplasty for fungal corneal ulcer","volume":"29","author":"Sonmez","year":"2009","journal-title":"Int Ophthalmol"},{"key":"R42-20260902","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bjo.85.9.1070","article-title":"Treatment of fungal keratitis by penetrating keratoplasty","volume":"85","author":"Xie","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R43-20260902","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00003226-200203000-00006","article-title":"Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis","volume":"21","author":"Perry","year":"2002","journal-title":"Cornea"},{"key":"R44-20260902","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/13693780701625149","article-title":"Corneal ulcer due to neocosmospora vasinfecta in an immunocompetent patient","volume":"46","author":"Manikandan","year":"2008","journal-title":"Med Mycol"},{"key":"R45-20260902","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ICO.0000000000002827","article-title":"Use of topical cyclosporine 0.1% in therapeutic penetrating keratoplasty for fungal keratitis","volume":"41","author":"Chatterjee","year":"2022","journal-title":"Cornea"},{"key":"R46-20260902","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/ICO.0000000000003268","article-title":"Repeated intracameral amphotericin B: a safe approach for management of fungal anterior chamber reactivations after therapeutic penetrating keratoplasty","volume":"42","author":"Okonkwo","year":"2023","journal-title":"Cornea"},{"key":"R47-20260902","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4155\/cli.14.135","article-title":"Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence","volume":"5","author":"Ames","year":"2015","journal-title":"Clin Investig"},{"key":"R48-20260902","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","article-title":"High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen","volume":"28","author":"Dastjerdi","year":"2009","journal-title":"Cornea"},{"key":"R49-20260902","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajo.2007.03.028","article-title":"Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty","volume":"144","author":"Nguyen","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R50-20260902","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00417-016-3412-0","article-title":"Therapeutic dilemma in fungal keratitis: administration of steroids for immune rejection early after keratoplasty","volume":"254","author":"Wang","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R51-20260902","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ophtha.2009.10.004","article-title":"Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation","volume":"117","author":"Shi","year":"2010","journal-title":"Ophthalmology"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:00:43Z","timestamp":1788390043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0000000000004166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000004166","relation":{},"ISSN":["0277-3740","1536-4798"],"issn-type":[{"value":"0277-3740","type":"print"},{"value":"1536-4798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2026-01-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}